Has Susmitha Dhanyamraju, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,396 in general payments to Susmitha Dhanyamraju, MD across 77 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susmitha Dhanyamraju, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susmitha Dhanyamraju, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susmitha Dhanyamraju, MD

Internal Medicine · Chester, PANPI 1346479946

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 70.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $5,315 and has fallen 89.0% since, to $587 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,396in general payments, 2019–2025

Across 77 payments — averaging $96.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Travere Therapeutics, Inc.$5K
Mallinckrodt Enterprises LLC$346
Otsuka America Pharmaceutical, Inc.$261
Amgen$256
AstraZeneca$252
Nxstage Medical, Inc.$244
plus $833 from 11 others

What the payments were for

Consulting fees$2,83038%
Travel & lodging$1,95926%
Food & beverage$2,50834%
Education$1001%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Travere Therapeutics, Inc.	12	$5,204
Mallinckrodt Enterprises LLC	11	$346
Otsuka America Pharmaceutical, Inc.	7	$261
Amgen(2 entities)	6	$256
AstraZeneca(2 entities)	10	$252
Nxstage Medical, Inc.	4	$244
Apellis Pharmaceuticals, Inc.	2	$153
OPKO Pharmaceuticals, LLC	8	$136
Ardelyx, Inc.	1	$125
Calliditas Therapeutics US Inc.	2	$119
Mallinckrodt Hospital Products Inc.	5	$109
Bayer	2	$53
Akebia Therapeutics Inc	2	$44
Ultragenyx Pharmaceutical Inc.	2	$37
Baxter Healthcare	1	$25
Fresenius USA Marketing, Inc.	1	$18
Avion Pharmaceuticals	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,396 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$89,956

Medicare patients

170

Services billed

509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
SamscaTolvaptan	11	$168,916
Calcitriol	15	$547
Hydralazine Hcl	16	$352
Losartan Potassium	13	$196
Furosemide	22	$157
Lisinopril	17	$108
Metoprolol Succinate	13	$66

Paid to pharmacies, not to this prescriber.

Other internal medicine in Chester

Jonathan EpsteinPhiladelphia$13.1M
Pitamber DevgonPhiladelphia$7.5M
Daniel RaderPhiladelphia$1.7M
Mohammed KidwaiBala Cynwyd$894K
Ronak BhimaniNorristown$623K
David GoldmannPhiladelphia$525K
Christopher StillDanville$442K
Jeffrey FreidLower Gwynedd$425K
Cheryl PegusSpring House$370K
Eyob FeyssaPhiladelphia$328K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →